ABSTRACT
INTRODUCTION
Multiple Sclerosis (MS) is a complex disease characterized by inflammatory foci in the central nervous system (CNS) causing a progressive demyelination of axons and neuronal cell degeneration, resulting in a severe disabling condition.
The pathogenesis of MS is not well understood, but it is well established that both genetic and environmental factors contribute together to the development of the disease.
Association with the human leukocyte antigen (HLA) genes from the major histocompatibility complex on chromosome 6p21.3 was identified almost 40 years ago. It is well established that the HLA-DRB1*1501 allele, tagging the DRB1*1501-DQB1*0602 (also known as DR15) haplotype in the HLA class II region, is the strongest genetic risk factor conferring an OR of approximately 3 in most studied populations. [1] [2] [3] [4] Through careful analysis of this complex region, which is characterized by an extreme polymorphism and extensive linkage disequilibrium, evidence for an independent effect on risk from the class I region has emerged. In 2007, IMSGC presented data from a large study based on UK and North American Caucasians suggesting that this signal might be determined by the HLA Cw*05 allele. The HLA Cw*05 allele was less frequent in patients than controls conferring a protective effect. [5] At the same time, two other groups identified an association between the HLA A*02 allele and MS with a similar OR in two populations (Swedish and Tasmanians) with a different genetic background. This allele, like HLA Cw*05, conferred a protective effect. [6, 7] We recently tested the association of both HLA A*02 and HLA Cw*05 in an Italian cohort of 1273 MS patients and 1075 controls. [8] Our analyses confirmed the protective effect of HLA A*02 whereas HLA Cw*05 did not present any independent association. However, the presence of HLA Cw*05 appeared to significantly enhance the protective effect due to HLA A*02 resulting in a 3 fold decreased OR for the HLA A*02-Cw*05 combination (OR = 0.22, 95% CI: 0.13-0.38) relative to the presence of HLA A*02 alone (OR = 0.69, 95% CI: 0.58-0.83). In the Caucasian population, the HLA A*02-Cw*05 combination is carried by two HLA extended haplotypes, namely HLA A*0201-Cw*0501-B*4402-DRB1*0401 and HLA A*0201-Cw*0501-B*1801-DRB1*1102 (also known as 44.1 and 18.3 haplotypes, respectively, [9] [10] [11] ). These two haplotypes are present in the Italian population with approximately the same frequency (Rendine, unpublished). Thus it is possible that the strong protective effect we detected for the A*02-Cw*05 combination is due to a haplotypic effect, i.e. to the presence of a primarily associated factor carried by one or both the above haplotypes. Interestingly HLA B*4402 was recently identified as an MS protective factor. [12, 13, 14] In order to better understand whether the enhanced protective effect of the HLA A*02-Cw*05 combination is due to a haplotypic effect or a direct interactive role of the two markers as well as test the possible role of B*44, in the present study we extended the analysis in our Italian cohort to the involved HLA-B alleles, namely HLA B*44 (and its subtypes B*4402 and B*4403) and B*18.
The association with MS of the various haplotypic combinations of the A*02-Cw*05 set with or without B*44 or B*18 was also analysed in a UK cohort fully typed for HLA-DR, -A,-B and -C, in order to verify our results in another population with a possibly different genetic background.
MATERIALS AND METHODS

Subjects
A total of 1445 Italian MS patients and 973 controls were analyzed for HLA-A*02, -Cw*05, -B*18
and -B*44 class I markers and for DRB1*15. Of these, 1433 patients and 950 controls were also typed for B*44 subtypes (4402 and 4403). The majority of the samples were recruited from NorthWest Italy and the remaining from Central Italy. Patients with Sardinian ancestors were excluded to avoid the introduction of a confounding source of heterogeneity.
Italian controls included medical students, university and hospital staff, blood donors (female:male ratio 1:1.1) matched for age and regional origin with the MS patients.
Patients (83%) and controls (91%) mostly overlap with those included in our previous paper [8] and were already typed for HLA-A*02, Cw*05 and DRB1*15. Selection for inclusion was based on DNA availability.
We also analysed a UK data set composed of 721 MS patients, 408 healthy matched controls and 480 family trios. These samples were described in detail elsewhere. [5] Patients were diagnosed according to McDonald et al. criteria. [15] All the samples, both Italian and British, were of European ancestry.
Features of the analyzed samples are shown in Table 1 . All the samples were collected after informed consent and appropriate ethical approvals.
HLA typing of Italian samples
HLA typing was performed using specific reactions in order to obtain information about the four All these protocols, with the exception of A*02, did not allow to distinguish between homozygotes and heterozygotes but only whether the samples were positive or negative for the tested markers.
These methods were validated testing 45 samples previously typed with standard protocols. The results were consistent for all tested samples.
HLA class I and class II typing of UK samples
All the UK samples had been previously completely typed for the HLA-A, -C, -B and -DRB1 loci as described in detail elsewhere. [5] The trio families were genotyped with a medium resolution method for all HLA class I (two-digit) and class II (four-digit) alleles. 
Statistical analysis
The association of each marker, haplotype or phenotype combination with the disease was measured by χ 2 test, the Odds Ratio (OR) and its 95% Confidence Intervals (95% CI). Allele and haplotype analyses of UK samples were performed with the UNPHASED v 3.0.13 program using the "certain haplotype only" option for family trios and the "uncertain haplotypes" option for the case/control cohort. [17] Linkage disequilibria (LD) were calculated from phenotypes according to Mattiuz et al. [18] .
Logistic regression was carried out to determine the effect of the considered markers on MS susceptibility. The association of each polymorphism with the disease was measured by the Odds Ratio (OR) and its 95% Confidence Intervals (95% CI). We used likelihood ratio tests (LRT) to assess the statistical significance of the models and to compare the models. The contribution of each variable was evaluated by comparing the LRTs derived from a model with and without the variable.
Reported p values were not corrected for the number of comparisons. (Table 2) .
RESULTS
Case
Association analysis in UK family trios
To A comparison of the results of the various tested populations and data sets is summarized in Table   5 . HLA-B*18 was not included because in the British population some of its combinations with A*02 and Cw*05 were very rare and none was significantly associated to MS (Table 3 and   Supplementary Tables 2, 3 , 4) and in both populations the logistic regression analysis ruled out a protective role of this marker ( Table 4 ).
The main conclusions that can be drawn from Table 5 are the following:
-The A*02-Cw*05-B*44/12 combination conferred a significant protection in both populations.
Actually, this was the only allele combination consistently associated in both populations and in all the tested panels.
-A significant protection was also observed for the Cw*05-B*12 combination in the absence of The typing strategy utilized for the Italian sample did not distinguish homozygotes from heterozygotes, making it impossible to deduce the haplotypic combinations of the tested alleles.
Therefore the detected associations were with phenotypic rather than haplotypic allele combinations and it was not possible to determine whether the involved alleles were carried in cis or in trans. The second population compensated for this limitation, since in the UK samples it was possible to determine the allele phase, either by family segregation (trios) or by computer algorithms (casecontrol In conclusion, this study contributes to the demonstration that the HLA class I region contains additional factors modulating MS susceptibility, independently of the well established DRB1 locus.
At least two independent protective effects are proposed which are tagged by the A*02-Cw*05 combination and the A*02 allele, respectively. The protective effect of the A*02-Cw*05-B*44
haplotype has a strength comparable to that of DRB1*15, which is the strongest MS risk factor, thus behaving as an important modulator of MS susceptibility. The A*02-Cw*05-B44 combination is relatively rare in both tested populations (4.6% and 15.0% of DR15 negative Italian and British controls respectively). However, it is likely that its highly protective effect is genuine, and not a spurious signal due to its low frequency or to stratification, since it was replicated in two independent samples belonging to two populations with a different genetic background.
The identification of the primarily associated factor/s requires an extended analysis of the involved haplotype/s in populations with different genetic background. This will help to elucidate the mechanism mediating the protective effect and hence to shed new light on MS pathogenesis. "None to declare" 
